OpenEvidence, which has been called “ChatGPT for doctors,” is raising $250 million in equity financing at a $12 billion valuation, The Information reported.
The three-year-old company, which secured $200 million in October to be valued at $6 billion, generates annual recurring revenue of $150 million, according to the Dec. 12 story.
The startup also landed a $75 million series A funding round in early 2025 and partnered with the American College of Cardiology in November to accelerate the translation of research into clinical practice. Becker’s reached out to OpenEvidence for comment on the report.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
